PRAME - Revision history

Michael at 21:23, 4 March 2025

2025-03-04T21:23:39Z

← Older revision		Revision as of 21:23, 4 March 2025
Line 18:		Line 18:

	[[Category:Immunohistochemistry]]		[[Category:Immunohistochemistry]]
	[[Category:~~Abbreviations~~]]		[[Category: Abbreviation]]

Michael at 21:23, 4 March 2025

2025-03-04T21:23:06Z

← Older revision		Revision as of 21:23, 4 March 2025
Line 18:		Line 18:

	[[Category:Immunohistochemistry]]		[[Category:Immunohistochemistry]]
			[[Category:Abbreviations]]

Michael at 21:20, 4 March 2025

2025-03-04T21:20:43Z

← Older revision		Revision as of 21:20, 4 March 2025
Line 2:		Line 2:

	==General==		==General==
			*PRAME is an acronym for ''PReferentially expressed Antigen in MElanoma''.

	==Positive staining==		==Positive staining==
	*80-85% of primary melanomas.<ref name=pmid30045064/>		*80-85% of primary melanomas.<ref name=pmid30045064/>
	*85-90% of metastatic melanomas.<ref name=pmid30045064/>		*85-90% of metastatic melanomas.<ref name=pmid30045064/>

			Pattern:<ref>{{cite journal \|authors=Lezcano C, Jungbluth AA, Busam KJ \|title=PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions \|journal=Surg Pathol Clin \|volume=14 \|issue=2 \|pages=165–175 \|date=June 2021 \|pmid=34023098 \|pmc=8152939 \|doi=10.1016/j.path.2021.01.001 \|url=}}</ref>
			*Nuclear staining.

	==See also==		==See also==

Michael at 21:18, 4 March 2025

2025-03-04T21:18:29Z

← Older revision		Revision as of 21:18, 4 March 2025
Line 1:		Line 1:
	'''PRAME''' is an [[immunostain]] that is typically positive in [[malignant melanoma]].<ref>{{cite journal \|authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ \|title=PRAME Expression in Melanocytic Tumors \|journal=Am J Surg Pathol \|volume=42 \|issue=11 \|pages=1456–1465 \|date=November 2018 \|pmid=30045064 \|pmc=6631376 \|doi=10.1097/PAS.0000000000001134 \|url=}}</ref>		'''PRAME''' is an [[immunostain]] that is typically positive in [[malignant melanoma]].<ref name=pmid30045064>{{cite journal \|authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ \|title=PRAME Expression in Melanocytic Tumors \|journal=Am J Surg Pathol \|volume=42 \|issue=11 \|pages=1456–1465 \|date=November 2018 \|pmid=30045064 \|pmc=6631376 \|doi=10.1097/PAS.0000000000001134 \|url=}}</ref>

			==General==

			==Positive staining==
			*80-85% of primary melanomas.<ref name=pmid30045064/>
			*85-90% of metastatic melanomas.<ref name=pmid30045064/>

	==See also==		==See also==

Michael: Created page with "'''PRAME''' is an immunostain that is typically positive in malignant melanoma.{{cite journal |authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ |t..."

2025-03-04T21:17:19Z

Created page with "'''PRAME''' is an immunostain that is typically positive in malignant melanoma.<ref>{{cite journal |authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ |t..."

New page

'''PRAME''' is an [[immunostain]] that is typically positive in [[malignant melanoma]].<ref>{{cite journal |authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ |title=PRAME Expression in Melanocytic Tumors |journal=Am J Surg Pathol |volume=42 |issue=11 |pages=1456–1465 |date=November 2018 |pmid=30045064 |pmc=6631376 |doi=10.1097/PAS.0000000000001134 |url=}}</ref>

==See also==
*[[Malignant melanoma]].

==References==
{{Reflist|1}}

[[Category:Immunohistochemistry]]